Brought to you by 
Cerenis brings in €50mm via its Series C round
21 Oct 2010
Executive Summary
Cerenis Therapeutics SA (cardiovascular and metabolic conditions) has raised €40mm ($51.9mm) through the first closing of its Series C venture round. The Fund for Strategic Investment provided €20mm and the remainder came from current shareholders Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, EDF Ventures, OrbiMed, and Daiwa Corporate Investment. The money will be used to continue developing Phase II CER001 for cardiovascular disease and to work on other HDL drug candidates. The same day it announced the Series C round, Cerenis received €10.7mm from the French government.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cerenis brings in €50mm via its Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice